Bristol Myers Squibb Presents Sotyktu Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy at the European Society of Cardiology Congress 2026
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for Patients with Multiple Myeloma, as Early as First Relapse
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Cascadia To Participate in the Gentile Mining Investor Forum and Michael Gentile Mining & Metals European Roadshow
Spartan Metals Geophysical Surveys Indicate Potential Tungsten-Silver Veins Extension at Its Tungstonia Claims, Nevada
